| Richard Loeffler, CRNA | |
|
1000 Pine St, Texarkana, TX 75501-5100 | |
| (903) 427-3851 | |
| Not Available |
| Full Name | Richard Loeffler |
|---|---|
| Gender | Male |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 31 Years |
| Location | 1000 Pine St, Texarkana, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043268071 | NPI | - | NPPES |
| 157567202 | Medicaid | TX | |
| 200010300A | Medicaid | OK | |
| 8168UU | Other | TX | BCBS |
| 1043268071 | Other | AR | BCBS |
| 149569701 | Medicaid | AR | |
| 157567206 | Medicaid | TX | |
| 157567205 | Medicaid | TX |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | 691794 (Texas) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Gpch Llc | 0042303232 | 16 |
News Archive
Cytomedix, Inc., a leading developer of biologically active regenerative therapies for wound care, inflammation and angiogenesis, today announced the closing of an agreement with Sorin Group, a global leader in the treatment of cardiovascular diseases, to acquire the Angel® Whole Blood Separation System and activAT® Autologous Thrombin Processing Kit for $7 million in cash, to be paid in installments over the next two and one-half years.
Some cancers, like breast and prostate cancer, are driven by hormones such as estrogen and testosterone, but to date, there are none that are driven by the lack of a hormone. New evidence suggests that human colon cells may become cancerous when they lose the ability to produce a hormone that helps the cells maintain normal biology. If verified by further studies, it suggests that treating patients at high risk for colon cancer by replacing the hormone guanylin could prevent the development of cancer.
The White House's chief technology officer, Todd Park, told the committee that teams are working aggressively to get the website functioning "for the vast majority" of consumers by the administration's Nov. 30 deadline. Meanwhile, a second panel heard testimony about website and security concerns.
For patients with advanced lung cancer whose tumors carry EGFR activating mutations, first-line treatment with erlotinib nearly tripled progression-free survival compared to a standard chemotherapy combination, show results from the first prospective Phase-III study to report findings in this setting.The new results from the OPTIMAL trial were reported at the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy.
› Verified 7 days ago
| Entity Name | Northstar Anesthesia Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1912978610 PECOS PAC ID: 7315907128 Enrollment ID: O20041015000685 |
News Archive
Cytomedix, Inc., a leading developer of biologically active regenerative therapies for wound care, inflammation and angiogenesis, today announced the closing of an agreement with Sorin Group, a global leader in the treatment of cardiovascular diseases, to acquire the Angel® Whole Blood Separation System and activAT® Autologous Thrombin Processing Kit for $7 million in cash, to be paid in installments over the next two and one-half years.
Some cancers, like breast and prostate cancer, are driven by hormones such as estrogen and testosterone, but to date, there are none that are driven by the lack of a hormone. New evidence suggests that human colon cells may become cancerous when they lose the ability to produce a hormone that helps the cells maintain normal biology. If verified by further studies, it suggests that treating patients at high risk for colon cancer by replacing the hormone guanylin could prevent the development of cancer.
The White House's chief technology officer, Todd Park, told the committee that teams are working aggressively to get the website functioning "for the vast majority" of consumers by the administration's Nov. 30 deadline. Meanwhile, a second panel heard testimony about website and security concerns.
For patients with advanced lung cancer whose tumors carry EGFR activating mutations, first-line treatment with erlotinib nearly tripled progression-free survival compared to a standard chemotherapy combination, show results from the first prospective Phase-III study to report findings in this setting.The new results from the OPTIMAL trial were reported at the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy.
› Verified 7 days ago
| Entity Name | Gpch Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1841497153 PECOS PAC ID: 0042303232 Enrollment ID: O20090311000280 |
News Archive
Cytomedix, Inc., a leading developer of biologically active regenerative therapies for wound care, inflammation and angiogenesis, today announced the closing of an agreement with Sorin Group, a global leader in the treatment of cardiovascular diseases, to acquire the Angel® Whole Blood Separation System and activAT® Autologous Thrombin Processing Kit for $7 million in cash, to be paid in installments over the next two and one-half years.
Some cancers, like breast and prostate cancer, are driven by hormones such as estrogen and testosterone, but to date, there are none that are driven by the lack of a hormone. New evidence suggests that human colon cells may become cancerous when they lose the ability to produce a hormone that helps the cells maintain normal biology. If verified by further studies, it suggests that treating patients at high risk for colon cancer by replacing the hormone guanylin could prevent the development of cancer.
The White House's chief technology officer, Todd Park, told the committee that teams are working aggressively to get the website functioning "for the vast majority" of consumers by the administration's Nov. 30 deadline. Meanwhile, a second panel heard testimony about website and security concerns.
For patients with advanced lung cancer whose tumors carry EGFR activating mutations, first-line treatment with erlotinib nearly tripled progression-free survival compared to a standard chemotherapy combination, show results from the first prospective Phase-III study to report findings in this setting.The new results from the OPTIMAL trial were reported at the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy.
› Verified 7 days ago
| Entity Name | Northstar Anesthesia Ii Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477066405 PECOS PAC ID: 2365701737 Enrollment ID: O20180110000102 |
News Archive
Cytomedix, Inc., a leading developer of biologically active regenerative therapies for wound care, inflammation and angiogenesis, today announced the closing of an agreement with Sorin Group, a global leader in the treatment of cardiovascular diseases, to acquire the Angel® Whole Blood Separation System and activAT® Autologous Thrombin Processing Kit for $7 million in cash, to be paid in installments over the next two and one-half years.
Some cancers, like breast and prostate cancer, are driven by hormones such as estrogen and testosterone, but to date, there are none that are driven by the lack of a hormone. New evidence suggests that human colon cells may become cancerous when they lose the ability to produce a hormone that helps the cells maintain normal biology. If verified by further studies, it suggests that treating patients at high risk for colon cancer by replacing the hormone guanylin could prevent the development of cancer.
The White House's chief technology officer, Todd Park, told the committee that teams are working aggressively to get the website functioning "for the vast majority" of consumers by the administration's Nov. 30 deadline. Meanwhile, a second panel heard testimony about website and security concerns.
For patients with advanced lung cancer whose tumors carry EGFR activating mutations, first-line treatment with erlotinib nearly tripled progression-free survival compared to a standard chemotherapy combination, show results from the first prospective Phase-III study to report findings in this setting.The new results from the OPTIMAL trial were reported at the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Richard Loeffler, CRNA Po Box 952270, Dallas, TX 75395-0001 Ph: (972) 715-5000 | Richard Loeffler, CRNA 1000 Pine St, Texarkana, TX 75501-5100 Ph: (903) 427-3851 |
News Archive
Cytomedix, Inc., a leading developer of biologically active regenerative therapies for wound care, inflammation and angiogenesis, today announced the closing of an agreement with Sorin Group, a global leader in the treatment of cardiovascular diseases, to acquire the Angel® Whole Blood Separation System and activAT® Autologous Thrombin Processing Kit for $7 million in cash, to be paid in installments over the next two and one-half years.
Some cancers, like breast and prostate cancer, are driven by hormones such as estrogen and testosterone, but to date, there are none that are driven by the lack of a hormone. New evidence suggests that human colon cells may become cancerous when they lose the ability to produce a hormone that helps the cells maintain normal biology. If verified by further studies, it suggests that treating patients at high risk for colon cancer by replacing the hormone guanylin could prevent the development of cancer.
The White House's chief technology officer, Todd Park, told the committee that teams are working aggressively to get the website functioning "for the vast majority" of consumers by the administration's Nov. 30 deadline. Meanwhile, a second panel heard testimony about website and security concerns.
For patients with advanced lung cancer whose tumors carry EGFR activating mutations, first-line treatment with erlotinib nearly tripled progression-free survival compared to a standard chemotherapy combination, show results from the first prospective Phase-III study to report findings in this setting.The new results from the OPTIMAL trial were reported at the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy.
› Verified 7 days ago
Mr. Brandon Wiley, C.R.N.A. Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 4100 Summerhill Rd, Texarkana, TX 75503 Phone: 903-735-9802 Fax: 903-735-9806 | |
Caleb Allen Bennett, Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 2600 Saint Michael Dr, Texarkana, TX 75503 Phone: 469-955-9423 | |
Brent Willis, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 203 La Grange Dr., Texarkana, TX 75501 Phone: 936-645-5428 | |
Charles David Lummus, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 4100 Summerhill Rd, Texarkana, TX 75503 Phone: 903-735-9802 Fax: 903-735-9806 | |
John Matt Hester, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 4100 Summerhill Rd, Texarkana, TX 75503 Phone: 903-735-9802 Fax: 903-735-9806 | |
Paul Mitchell James, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 4100 Summerhill Rd, Texarkana, TX 75503 Phone: 903-735-9802 Fax: 903-735-9806 |